Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.3700
+0.0120 (3.35%)
At close: May 12, 2025, 4:00 PM
0.3610
-0.0090 (-2.43%)
After-hours: May 12, 2025, 7:38 PM EDT
Bolt Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Bolt Biotherapeutics stock have an average target of 1.13, with a low estimate of 1.00 and a high estimate of 1.25. The average target predicts an increase of 205.41% from the current stock price of 0.37.
Analyst Consensus: Hold
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for Bolt Biotherapeutics stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 25, 2025 |
| Stifel | Stifel | Hold Maintains $1.5 → $1.25 | Hold | Maintains | $1.5 → $1.25 | +237.84% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 15, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $3 → $1 | Buy → Hold | Downgrades | $3 → $1 | +170.27% | May 15, 2024 |
Financial Forecast
Revenue This Year
2.90M
from 7.69M
Decreased by -62.29%
Revenue Next Year
5.15M
from 2.90M
Increased by 77.48%
EPS This Year
-1.45
from -1.65
EPS Next Year
-1.05
from -1.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.3M | 15.9M | 38.4M | ||
| Avg | 2.9M | 5.1M | 14.0M | ||
| Low | n/a | n/a | 196,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -31.2% | 449.1% | 646.2% | ||
| Avg | -62.3% | 77.5% | 172.1% | ||
| Low | - | - | -96.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -0.59 | -0.36 | ||
| Avg | -1.45 | -1.05 | -0.38 | ||
| Low | -1.81 | -1.89 | -0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.